Department of Oncology, Førde Central Hospital, University of Bergen, Bergen, Norway.
Dis Esophagus. 2011 Jan;24(1):39-47. doi: 10.1111/j.1442-2050.2010.01104.x. Epub 2010 Sep 2.
Curative treatment of esophageal cancer with definitive or preoperative high-dose chemoradiotherapy inflicts a major strain on the patients with potentially severe physical, emotional, and social consequences. The aim of this study was to assess various aspects of quality of life and fatigue in long-term survivors following such a treatment. Patients undergoing a potentially curative treatment between 1996 and 2007, and still alive (n= 41) completed quality of life questionnaires of the European Organization for Research and Treatment of Cancer core questionnaire (QLQ-C30) and esophageal cancer module (QLQ-OES18). Twenty patients were treated by surgery alone, and 21 patients were scheduled for high-dose chemoradiotherapy followed by surgery. Five of those patients did not undergo planned surgery. Preoperative chemoradiotherapy consisted of three courses of chemotherapy, cisplatin 100 mg/m(2) and 5-fluorouracil 5000 mg/m(2) in each course and concomitant radiotherapy of a median dose 66 Gy. Quality of life in esophageal cancer patients receiving high-dose chemoradiotherapy was compared with that for esophageal cancer patients who received only surgery, head and neck cancer patients, laryngectomized patients, and a random sample of the general Norwegian population. Esophageal cancer patients treated by high-dose chemoradiotherapy had significantly worse global quality of life as reflected by almost all functional scales and higher fatigue compared with esophageal cancer patients who received surgery alone, head and neck cancer patients, and the general Norwegian population. There were no significant differences in quality of life between the esophageal cancer patients receiving high-dose chemoradiotherapy and the laryngectomy patients. Further, the esophageal cancer patients receiving high-dose chemoradiotherapy had higher intensity of other symptoms like general pain, insomnia, nausea/vomiting, diarrhea, and constipation compared with the esophageal cancer patients who received surgery alone, head and neck cancer patients, and the general Norwegian population. High-dose chemoradiotherapy with cisplatin and 5-fluorouracil had a considerable negative long-term effect on global quality of life in patients with resectable esophageal cancer. Fatigue was a prominent long-lasting symptom in these patients.
根治性或术前高剂量放化疗治疗食管癌会给患者带来严重的身体、情绪和社交方面的压力。本研究旨在评估此类治疗后长期生存者的生活质量和疲劳的各个方面。1996 年至 2007 年间接受潜在根治性治疗且仍存活的患者(n=41)完成了欧洲癌症研究与治疗组织核心问卷(QLQ-C30)和食管癌模块(QLQ-OES18)的生活质量问卷。20 例患者单独接受手术治疗,21 例患者接受高剂量放化疗后手术治疗。其中 5 例患者未行计划手术。术前放化疗包括三个疗程的化疗,每个疗程顺铂 100mg/m²和氟尿嘧啶 5000mg/m²,同时给予中位剂量 66Gy 的放射治疗。接受高剂量放化疗的食管癌患者的生活质量与仅接受手术、头颈部癌症患者、喉切除术患者和挪威一般人群的随机样本进行了比较。接受高剂量放化疗的食管癌患者的整体生活质量明显较差,几乎所有功能量表都反映了这一点,而且疲劳程度也高于仅接受手术的食管癌患者、头颈部癌症患者和挪威一般人群。接受高剂量放化疗的食管癌患者与接受喉切除术的患者在生活质量方面没有显著差异。此外,接受高剂量放化疗的食管癌患者的其他症状如一般疼痛、失眠、恶心/呕吐、腹泻和便秘的强度也高于仅接受手术的食管癌患者、头颈部癌症患者和挪威一般人群。顺铂和氟尿嘧啶联合高剂量放化疗对可切除食管癌患者的整体生活质量产生了相当大的负面影响。疲劳是这些患者长期存在的突出症状。